Lesley Ann Calhoun

Lesley Ann Calhoun is recorded as COO at Aligos Therapeutics, Inc. (ALGS) since January 30, 2025, CFO at Aligos Therapeutics, Inc. (ALGS) and Board Member at Tango Therapeutics, Inc. (TNGX) since January 1, 2021. The newest filing on record that lists Lesley Ann Calhoun as CFO at Aligos Therapeutics, Inc. (ALGS) is dated April 29, 2026. The newest filing on record that lists Lesley Ann Calhoun as Board Member at Tango Therapeutics, Inc. (TNGX) is dated April 17, 2026. Aligos Therapeutics, Inc. reported in an 8-K filed February 3, 2025 that Lesley Ann Calhoun was appointed Chief Operating Officer, effective January 30, 2025. The proxy statement of Aligos Therapeutics, Inc. reports total compensation of $1,579,689 for Lesley Ann Calhoun in fiscal 2025, including a base salary of $502,000. Disclosed compensation is on record for 2 fiscal years. Aligos Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Tango Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Aligos Therapeutics, Inc. includes Lawrence M. Blatt (CEO and Board Member), Lucinda Y. Quan (General Counsel), Nikhil Aneja (Chief Accounting Officer) and 7 others.